Prostate cancer is the most common cancer found in males within the developed world and the second most prevalent cause of deaths related to cancer1, with the possibility that the rate of prostate cancer-related mortality could double by 20302. Currently, methods used to diagnose prostate cancer involve measuring Prostate Specific Antigen (PSA) within a blood sample, a digital rectal examination (DRE) and a Trans-Rectal Ultrasound (TRUS) guided biopsy1. There are limitations to these methods, such as the poor specificity of PSA measurement and DRE, because PSA levels can rise not only due to the presence of prostate cancer but also due to inflammation or Benign Prostatic Hyperplasia (BPH)3. TRUS biopsy methods have been shown to have poorer sensitivity for significant prostate cancer and often detect a cancer that may not affect the patient during the course of...
Sign in to your account
Log in
This content is available to registered users only. Please sign in to continue.
If you are not yet registered, please create your account on www.sor.org and verify your membership status. Once your account has been set up, return here and sign in to access the content.
Set up your account